Review
Open access
Oct 2026
BACKGROUND AIMS
To evaluate safety and efficacy of FGFR1-3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements (FGFR2F), mutations (FGFR2M), or amplifications (FGFR2A), previously treated with chemotherapy.
APPROACH RESULTS
Open-label, non-contro...
M. Borad, Michele Droz Dit Busset, M. Javle et al.
· Hepatology · 0 citations